A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03159403|
Recruitment Status : Completed
First Posted : May 18, 2017
Last Update Posted : March 12, 2018
|Condition or disease||Intervention/treatment|
|Gram-Positive Bacterial Infections||Drug: Oritavancin|
|Study Type :||Observational|
|Actual Enrollment :||325 participants|
|Official Title:||Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting|
|Actual Study Start Date :||April 12, 2017|
|Actual Primary Completion Date :||February 15, 2018|
|Actual Study Completion Date :||March 8, 2018|
Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
Other Name: Orbactiv®
- Types Of Primary Infections Being Treated With Oritavancin [ Time Frame: Day 1 ]The Types Of Primary Infections refers to whether the primary infection was skin or skin structure or other systemic infection (for example, bacteremia, prosthetic joint infection, osteomyelitis).
- Classification Of Primary Infections Being Treated With Oritavancin [ Time Frame: Day 1 ]The classification of primary infection refers to whether a skin or skin structure infection was cellulitis, abscess, wound, or other.
- Proportion Of Participants With Positive Cultures For Gram Positive, Gram Negative, And Anaerobic Pathogens From The Infected Site [ Time Frame: Up to 30 days after oritavancin IV infusion ]All microbiology results during the infection event will be reported. Microbiology results will be noted only for the infection site for which oritavancin (in addition to other agents) is administered or other site related to the primary infection in case of multiple infections. An adverse event was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
- Duration Of Treatment With Oritavancin [ Time Frame: Day 1 through end of oritavancin IV infusion ]The number of days of treatment with oritavancin will be presented.
- Proportion Of Participants With A Clinical Outcome Of Cure, Improved, or Failure [ Time Frame: Up to 30 days after oritavancin IV infusion ]
Clinical assessments will be based on participant records between end of infusion to 30 days following the last dose of Oritavancin. Clinical categories for assessment include:
- Cure - Clinical signs and symptoms are resolved, and no additional antibiotic therapy is necessary for the treatment of the infection
- Improved - Partial resolution of clinical signs and symptoms, and no additional antibiotic therapy is necessary for the treatment of the infection
- Failure - Inadequate resolution, or new or worsening clinical signs and symptoms, such that additional antibiotic therapy is necessary for treatment of the infection
- Non-evaluable - Unable to determine response because the participant record did not contain the necessary information to determine cure, improvement, or failure
- Proportion Of Participants With A Microbiologic Eradication Or Microbiologic Persistence [ Time Frame: Up to 30 days after oritavancin IV infusion ]
Microbiological assessments will be based on participant records between end of infusion to 30 days following the last dose of oritavancin. Microbiological categories will include only gram positive pathogens believed to be related to the infection process and are defined as:
- Microbiologic eradication (the baseline gram positive pathogen has been eradicated)
- Microbiologic persistence (the baseline gram positive pathogen persists)
- Culture drawn post-oritavancin therapy, but no information regarding microbiologic culture results
- No culture collected following the last dose of oritavancin
- No information available
- Use Of Concomitant Antibiotics With Oritavancin [ Time Frame: Day 1 through end of oritavancin IV infusion ]Concomitant antibiotics include those used between the first and last dose of oritavancin. The number of participants and the type of antibiotic taken will be presented.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03159403
Show 21 Study Locations
|Study Director:||Medical Information||Global Health Science Center|